Assertio Provides Response to Letter from Short-seller
Assertio Holdings (NASDAQ: ASRT) has issued a response to allegations made by short-seller Alex Parker of Buxton Hemsley Group. CEO Brendan O'Grady strongly refuted claims about Rolvedon's safety and the company's accounting practices, stating they are false and baseless. The company revealed that Parker, who initially positioned himself as an activist investor, attempted to negotiate payment of his legal fees in exchange for dropping his activist activities. After unsuccessful attempts to extract money and a board position, Parker has now shifted to a short-selling position. Assertio is considering legal and regulatory action in response.
Assertio Holdings (NASDAQ: ASRT) ha emesso una risposta alle accuse formulate dal venditore allo scoperto Alex Parker del Buxton Hemsley Group. Il CEO Brendan O'Grady ha fortemente smentito le affermazioni riguardanti la sicurezza di Rolvedon e le pratiche contabili dell'azienda, dichiarando che sono false e infondate. L'azienda ha rivelato che Parker, che inizialmente si era presentato come un investitore attivista, ha tentato di negoziare il pagamento delle sue spese legali in cambio della cessazione delle sue attività attiviste. Dopo vari tentativi falliti di estrarre denaro e una posizione nel consiglio, Parker ha ora cambiato strategia passando alla vendita allo scoperto. Assertio sta considerando azioni legali e regolatorie in risposta.
Assertio Holdings (NASDAQ: ASRT) ha emitido una respuesta a las acusaciones realizadas por el vendedor en corto Alex Parker del Buxton Hemsley Group. El CEO Brendan O'Grady refutó firmemente las afirmaciones sobre la seguridad de Rolvedon y las prácticas contables de la empresa, afirmando que son falsas y sin fundamento. La compañía reveló que Parker, quien inicialmente se presentó como un inversor activista, intentó negociar el pago de sus honorarios legales a cambio de abandonar sus actividades activistas. Después de intentos fallidos de obtener dinero y un puesto en la junta, Parker ha cambiado ahora a una posición de venta en corto. Assertio está considerando acciones legales y regulatorias en respuesta.
Assertio Holdings (NASDAQ: ASRT)는 Buxton Hemsley Group의 공매도 투자자 Alex Parker가 제기한 주장에 대한 응답을 발표했습니다. CEO Brendan O'Grady는 Rolvedon의 안전성 및 회사의 회계 관행에 관한 주장을 강력히 반박하며, 이들이 거짓이며 근거가 없다고 밝혔습니다. 회사는 초기에는 행동주의 투자자로 자신을 자리매김한 Parker가 자신의 법적 비용을 지불받는 대가로 행동주의 활동을 중단하려고 했다고 밝혔습니다. 돈과 이사직을 얻으려는 시도가 실패한 후, Parker는 현재 공매도 포지션으로 전환하였습니다. Assertio는 이에 대한 법적 및 규제 조치를 고려하고 있습니다.
Assertio Holdings (NASDAQ: ASRT) a publié une réponse aux allégations formulées par le vendeur à découvert Alex Parker du groupe Buxton Hemsley. Le PDG Brendan O'Grady a fermement démenti les affirmations concernant la sécurité de Rolvedon et les pratiques comptables de l'entreprise, affirmant qu'elles sont fausses et sans fondement. L'entreprise a révélé que Parker, qui s'était initialement positionné comme un investisseur activiste, avait tenté de négocier le paiement de ses frais juridiques en échange de l'abandon de ses activités activistes. Après des tentatives infructueuses d'extraction d'argent et d'acquisition d'un poste au conseil, Parker a maintenant changé de position pour celle de la vente à découvert. Assertio envisage des actions légales et réglementaires en réponse.
Assertio Holdings (NASDAQ: ASRT) hat eine Antwort auf die Vorwürfe des Leerverkäufers Alex Parker von der Buxton Hemsley Group veröffentlicht. CEO Brendan O'Grady hat die Behauptungen zur Sicherheit von Rolvedon und den Buchhaltungspraktiken des Unternehmens entschieden zurückgewiesen und erklärt, dass sie falsch und unbegründet sind. Das Unternehmen gab bekannt, dass Parker, der sich zunächst als aktivistischer Investor positioniert hatte, versucht hat, die Zahlung seiner Anwaltskosten im Austausch für die Einstellung seiner aktivistischen Aktivitäten zu verhandeln. Nach gescheiterten Versuchen, Geld und einen Vorstandsposten zu erpressen, hat Parker nun zu einer Leerverkaufsposition gewechselt. Assertio erwägt rechtliche und regulatorische Schritte als Reaktion darauf.
- None.
- Company facing allegations regarding safety and approval of key product Rolvedon
- Dealing with accusations about accounting practices related to Spectrum merger
- Management resources being diverted to address short-seller claims
- Potential legal proceedings may result in additional costs
Insights
This response to short-seller allegations represents a significant development for Assertio. The CEO's forceful rebuttal addresses two critical areas: Rolvedon's BLA approval integrity and accounting practices related to the Spectrum merger. The short-seller's transition from activist investor to short position, after failed attempts to extract concessions, suggests potential market manipulation.
The company's consideration of legal and regulatory action against the short-seller could lead to regulatory investigations and litigation costs. However, the timing of this response before Q3 earnings demonstrates management's confidence in their position and commitment to transparency. The thorough professional review of Rolvedon's BLA and confirmation of proper accounting practices provide strong defensive positions against the allegations.
The market impact of this short-seller dispute extends beyond immediate stock volatility. Key considerations include:
- The short-seller's assets under management (
$3 million ) suggests minimal institutional backing - The company's defense of its Spectrum merger accounting practices is important for financial statement credibility
- The timing ahead of Q3 earnings indicates management's confidence in their financial position
Claims about Rolvedon and Assertio’s Accounting Practices are False and Baseless
Short-seller’s Press Release is Another Improper Attempt to Enrich Himself at Assertio’s Expense
Company Considering Taking Legal and Regulatory Action
LAKE FOREST, Ill., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, today issued the following letter from Chief Executive Officer Brendan O’Grady in response to public comments made November 8, 2024 by a short-seller:
To the members of the investment community,
As many of you have been aware, Mr. Alex Parker, who operates Buxton Hemsley Group, Inc. (an investment advisor reporting
Specifically, Mr. Parker made categorically false allegations concerning the safety and approval of Rolvedon and Assertio’s accounting practices. First, the Rolvedon BLA was fully reviewed by multiple professional firms who had access to the allegations made by the purported whistleblowers. Second, as Assertio has previously disclosed, the accounting charges for intangible asset impairments following the Spectrum merger were made in accordance with clear accounting principles. These facts have been communicated with the relevant details to Mr. Parker multiple times.
After six months of unsuccessful attempts to extract money and a board position from Assertio, Mr. Parker, through his lawyers, contacted our legal team and proposed that Assertio pay his legal fees in exchange for dropping his activist activities. Our legal team asked BHG’s counsel to put his offer on paper for our board to review and discuss. That was two weeks ago and an offer from Mr. Parker never came.
Instead, this past Friday, November 8, Mr. Parker shifted tactics, again releasing a number of false statements and baseless allegations against the company. At the same time, he stated he moved from activist investor to a short seller of our stock. We are reviewing all legal options, including referring Mr. Parker to the appropriate regulatory and enforcement authorities. We will continue to vigorously refute these baseless assertions against Assertio.
I want to assure you that I am confident that there has been no wrongdoing on the part of Assertio. I look forward to our Q3 earnings release and call later today and to putting this distraction behind us so we can focus on our mission to grow Assertio and deliver value to the patients we serve as well as all of our stakeholders.
Sincerely,
Brendan O’Grady
Chief Executive Officer and Board Member
Assertio Holdings, Inc.
About Assertio
Assertio is a commercial pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients. We have built our commercial portfolio through acquisition or licensing of approved products. Our commercial capabilities include marketing through both a sales force and a non-personal promotion model, market access through payor contracting, and trade and distribution. To learn more about Assertio, visit www.assertiotx.com.
Forward Looking Statements
Statements in this communication that are not historical facts are forward-looking statements that reflect Assertio’s current expectations, assumptions and estimates of future performance and economic conditions. These forward-looking statements are made in reliance on the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements relate to, among other things, future events or the future performance or operations of Assertio, including risks related to the subject matter of this communication and our ability to realize the benefits from our operating model, deliver or execute on our business strategy, including to expand or diversify our asset base and market reach and drive cash flows and growth, successfully integrate new assets, and explore new business development initiatives. All statements other than historical facts may be forward-looking statements and can be identified by words such as “anticipate,” “believe,” “could,” “design,” “estimate,” “expect,” “forecast,” “goal,” “guidance,” “imply,” “intend,” “may,” “objective,” “opportunity,” “outlook,” “plan,” “position,” “potential,” “predict,” “project,” “prospective,” “pursue,” “seek,” “should,” “strategy,” “target,” “would,” “will,” “aim” or other similar expressions that convey the uncertainty of future events or outcomes and are used to identify forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors, some of which are beyond the control of Assertio, including the risks described in Assertio’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the U.S. Securities and Exchange Commission (“SEC”) and in other filings Assertio makes with the SEC from time to time.
Investors and potential investors are urged not to place undue reliance on forward-looking statements in this communication, which speak only as of this date. While Assertio may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to update or revise any forward-looking-statements contained in this press release whether as a result of new information or future events, except as may be required by applicable law.
Investor Contact
Matt Kreps, Managing Director
Darrow Associates
M: 214-597-8200
mkreps@darrowir.com
FAQ
What allegations did short-seller Alex Parker make against Assertio (ASRT)?
How did Assertio (ASRT) respond to the short-seller's allegations on November 11, 2024?